Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185794 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT02185794 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 101 participants.
The verdict
NCT02185794, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.
Interventions
- DRUG SOF/VEL
- DRUG Voxilaprevir
- DRUG Placebo to match voxilaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2014-06-13 |
| Est. Completion | 2015-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02185794
The ClinicalTrials.gov registry entry for NCT02185794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SOF/VEL is the first listed.
NCT02185794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02185794 about?
NCT02185794 is a clinical study titled "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection". The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. ...
What is the current status of trial NCT02185794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2014-06-13. Estimated completion is 2015-09-28.
What interventions are being tested in trial NCT02185794?
The interventions under investigation include: SOF/VEL (DRUG), Voxilaprevir (DRUG), Placebo to match voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT02185794?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.